Board of Directors

Guiding our bold vision and strategy

Professor Sir John Bell

Chairman

Professor Sir John Bell

Chairman

Professor Sir John Bell was appointed to the Immunocore Board in March 2015. Professor Bell is the Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research. He is regarded as one of the world’s most distinguished scientists in the fields of genomic and genetic research and immunology, also has significant experience in the Healthcare industry, having been a founding director at three biotechnology companies; Avidex Ltd (a precursor to Immunocore which was acquired by MediGene in 2006), Oxagen and PowderJect Pharmaceuticals plc (acquired by Chiron Corporation in 2003). He currently also serves on the boards of Roche and Genentech and had a previous role on the scientific advisory board at AstraZeneca. Professor Bell was involved in the founding of the Wellcome Trust Centre for Human Genetics at Oxford University, now chairs the scientific committee of UK Biobank and the Global Health Scientific Advisory Board of the Bill and Melinda Gates Foundation, and is one of three Life Science Champions for the UK, reporting to the UK Prime Minister. His research has contributed significantly to the understanding of immune activation in a number of auto-immune diseases.

Dr. Bahija Jallal

Chief Executive Officer

Dr. Bahija Jallal

Chief Executive Officer

Dr. Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore. Prior to joining Immunocore in January 2019, she was President of MedImmune, Astra Zeneca’s global biologics research and development unit. She was also Executive Vice President of AstraZeneca and a member of its senior executive team.

Dr. Jallal serves on the Board of Anthem, Inc. and is a member of the Board of Trustees of the Johns Hopkins University and the Board of Directors of the University of Maryland Health Sciences Research Park Corporation.

Dr. Jallal has authored over 70 peer-reviewed publications and has more than 15 patents. She is a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine. She is also the immediate past President of the Association of Women in Science. Dr. Jallal was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association.

Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc.

Dr. Jallal received a master’s degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in ParisVI. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

Dr. Jean-Michel Cosséry

Non-Executive

Dr. Jean-Michel Cosséry

Non-Executive

Jean-Michel Cosséry, Ph.D is a senior Healthcare Executive with global leadership experience in research, marketing and commercial roles within med-tech and pharmaceuticals. Dr. Cosséry spent 10 years at GE Healthcare as the Chief Marketing Officer and Vice-President Global Marketing. He represented GEHC at the GE Strategic Board level and he was a member of the board for the Wipro-GE Healthcare join venture in India.  More recently, Dr. Cosséry was with Eli-Lilly acting as Vice-President, North American Oncology, as well as Managing Director Northern Europe (including the UK and Ireland). Externally, Dr. Cosséry represented Lilly in the CEO Forum in Washington DC, was a board member of the ABPI and the Chairman of the Board of the American Pharmaceutical Group.

Dr. Cosséry holds an MBA from the Rotterdam School of Management (Erasmus University), The Netherlands. He received his Ph.D with honours in Nuclear Chemistry and Neurobiology from University Paris, France, and conducted post-doctoral research in Neuropharmacology at the NIH in the United States. Additionally, he holds a Pharm D with honours in Pharmacology from the University of Paris.

Mr. Travis Coy

Non-Executive

Mr. Travis Coy

Non-Executive

Travis Coy is currently Vice President, Transactions - Oncology and Diagnostics, Corporate Business Development at Eli Lilly and Company. Prior to this role, Mr. Coy was responsible for leading and managing business development transactions for Lilly’s cardiometabolic disease, drug delivery, and device efforts. He has had a variety of finance and business development experiences at Lilly, including positions as Finance Director of Lilly’s Oncology Business Unit, Director of Investor Relations, Director of Corporate Finance and Investment Banking, and other financial controllership roles. Travis’ business development experiences have encompassed responsibilities ranging from managing the strategic and economic analyses of transactions to leading contract negotiations to having financial leadership of alliances. Before transitioning to finance and business development, he was a chemist in Lilly’s research laboratories and a production manager for Milliken & Company.

Mr. Ian Laing

Non-Executive

Mr. Ian Laing

Non-Executive

Mr. Ian Laing has served as a Non-Executive Director of Immunocore since 2008 and is a founder shareholder of the company. Having started his career in commercial property, Mr. Laing has been an active investor in life science and technology businesses for 25 years. He was previously a founder shareholder and Non-Executive Director of Oxford Asymmetry International plc (subsequently Evotec) from 1992 to 2000, Doctors.net.uk, Oxagen and Oxford Semiconductor Ltd. He is currently a Non-Executive Director of several private companies including Aegate Ltd, Phosphonics Ltd and SQW Group Ltd. Mr. Laing is a Trustee of the Nuffield Medical Trust and was formerly Deputy Chairman of London Business School and a Non-Executive Director of the Oxford Radcliffe Hospitals NHS Trust. He is a Governor of the Royal Shakespeare Company and a Barclay Fellow of Green Templeton College and an Honorary Fellow of St. Edmund Hall in the University of Oxford. Mr. Laing holds a MA degree from the University of Oxford and an MBA from London Business School.

Mr. Rob Perez

Non-Executive

Mr. Rob Perez

Non-Executive

Rob Perez is an Operating Partner and part of General Atlantic’s Operations Group, providing strategic support and advice to the firm’s investment team and portfolio companies with a particular focus on the biopharma and life sciences sectors. Before joining General Atlantic in 2019, he was Managing Director of Vineyard Sound Advisors, LLC, an advisory practice focused on growth companies in the biopharma industry. Prior to that, Rob was President and CEO of Cubist Pharmaceuticals, Inc. before its sale to Merck in 2015. Before joining Cubist in 2003, he served as Vice President of Biogen, Inc.’s CNS Business Unit.

Ms. Kristine Peterson

Non-Executive

Ms. Kristine Peterson

Non-Executive

Kristine Peterson was appointed to the Immunocore Board of Directors as a Non-Executive Director in January 2018. Ms. Peterson has more than 30 years’ experience in the global pharmaceutical and biotech industry.  Her most recent role was as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early stage R&D through to commercialisation, achieving approval by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the company’s Type 2 diabetes drug-device. In addition, Kristine raised more than $200 million in equity financing and prepared the company for its public listing on NASDAQ. Prior to Valeritas, Kristine was Company Group Chair at Johnson & Johnson for their worldwide biotech and oncology groups, growing those businesses to more than $6 billion in sales, launching several new products, and re-establishing the foundation for oncology R&D. She was also President and Senior Vice President, Commercial Operations for Biovail Corporation with responsibility for the US and Canadian business units. Earlier in her career, Kristine spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit.

Kristine continues to play a role on several other Boards of Directors at pharmaceutical and biotech companies including Amarin Corporation, Paratek Pharmaceuticals, Enanta Pharmaceutics, pSivida, and ImmunoGen. She is also a senior advisor to the Healthcare Businesswomen’s Association and a former Member of the Biotechnology Industry Organization Board.